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Abstract
Background: The relationship between proton pump inhibitor therapy and other acid suppressing
medications and the risk of gastrointestinal infections remains controversial.
Methods: Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and
other acid hypersecretory states had interval histories taken every six months regarding
hospitalizations or other intercurrent medical conditions. All medications taken were also
reviewed at each visit. In addition, available patients were specifically queried during the study
period 2006–2007 regarding the development of any gastrointestinal infections, hospitalizations,
and prescriptions for antibiotics.
Results: Ninety patients were enrolled in our long-term study and 81 were available for review.
The median basal gastric pH for the cohort after stabilization on therapy was 2.9 and ranged from
1.1 – 8.4 with a median pentagastrin stimulated gastric pH of 1.60 (range 1.0 – 8.2). No patient
developed a clinically significant gastrointestinal infection during the study. The median patient
years of follow-up were 6.25 years.
Conclusion: In a cohort of patients with gastric acid hypersecretion in whom acid secretion status
was monitored on lansoprazole, all were free of significant gastrointestinal infections on long-term
follow-up.
Trial registration: NCT00204373
Background
Acid suppressive therapy with proton pump inhibitors is
widespread, and their use has been associated with the
development of gastrointestinal infections [1]. Recent
studies raise concern that the use of these drugs may be
linked to the development of C. difficile colitis [2-4]. Such
observations have important implications given the
extensive use of these drugs worldwide.
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A cohort of patients with Zollinger-Ellison syndrome
(ZES) and other hypersecretory conditions/pseudo ZES
have been followed prospectively over a 18 year period as
part of an ongoing study evaluating the efficacy and safety
of lansoprazole therapy. In this protocol, patients
undergo gastric acid analysis on a six monthly basis as
well as evaluation for intercurrent illnesses or change in
medical condition. Such a cohort provides a unique
opportunity to evaluate the incidence of gastrointestinal
infections and any relationship to the degree of gastric
acid suppression over a prolonged period of continuous
therapy.
Methods
The protocol for patient evaluation and management has
been previously published [5]. Briefly, patients with gas-
tric acid hypersecretion were defined as a basal acid out-
put > 15 mmol/h in patients without prior antrectomy or
> 5 mmol/h after antrectomy. ZES was diagnosed by ele-
vated fasting or secretin-stimulated gastrin levels and/or
histologic identification of a gastrinoma. Sixty six patients
had been treated for a median of 0.8 years, range 0.1–5,
with omeprazole or other proton pump inhibitors before
entering this study. Gastric acid analysis measuring basal
and maximal stimulated acid secretion was performed at
entry and at six month intervals following normalization
of acid secretion with lansoprazole. Lansoprazole doses
were individually titrated in each patient to maintain
basal acid output (BAO) < 5 mmol/h a benchmark based
on upper limit for healthy control subjects or < 2 mmol/h
post-antrectomy.
Following initial stabilization of gastric acid secretion as
noted above, patients were evaluated on a six monthly
basis with history, physical examination, endoscopy with
gastric biopsies, gastric analysis, serum gastrin, and other
routine blood chemistry studies. Patients were also inter-
viewed at each visit for any intercurrent illnesses, hospital-
ization/illness, and change in medications. All patients
underwent interval physical examination and then under-
went endoscopy by one of the authors throughout the
study. In addition, over the last two years (2006–2007),
when patients were seen in follow-up, they were specifi-
cally queried regarding the development of any gastroin-
testinal infections or other diarrheal illnesses while
receiving lansoprazole with particular attention to epi-
sodes where the patient sought medical attention, had
stool studies performed, or received antibiotics for ther-
apy. All medical records for these hospitalizations were
obtained whenever possible. In addition, patients were
specifically queried about the use of antibiotics during the
hospitalization or any received as an outpatient.
Fasting gastric analysis was performed every six months in
the two hours before the next scheduled dose of lansopra-
zole. Each study comprised six consecutive ten-minute
aspiration periods for one hour of basal secretion fol-
lowed for one hour with stimulation by 6 ug/kg of penta-
gastrin (which accurately reflects maximal acid output
with food [6]) or, more recently, as pentagastrin has
become unavailable in the U.S., by modified sham feed-
ing (vagal stimulation) [7]. In each sample, volume, pH,
and titratable acid, were measured. The dose of lansopra-
zole was individually adjusted to maintain BAO at less
than 5 mmol/hr, but to avoid excessive acid suppression.
These data were used to determine whether, and to what
extent, acid secretion was sufficiently suppressed to pH
above 3.5, i.e., above the range of peptic activity [8]. We
have further defined achlorhydria, for the purposes of this
study, as a gastric pH above 5.0 – i.e., outside the range of
any kind of gastric proteolysis, and bactericidal activity.
The study has received approval from our institutional
review board during its 18 years (IRB# F030107005). All
patients gave written informed consent for the study.
Results
Demographic information of the patients at study entry is
shown in Table 1.
Lansoprazole was given for 2 – 207 months with a median
of seventy five months, representing a total of 45,862
patient-months of treatment. For the cohort, following
stabilization, the median BAO was 2.4 +/- 0.3. Likewise,
following stabilization, the median PAO was appropri-
ately suppressed (Table 2). After lansoprazole treatment,
the median gastric pH was 2.9 at basal level and 1.6 after
stimulation with either pentagastrin or sham feeding.
Optimized effective doses of lansoprazole varied from 15
mg every other day to 450 mg per day with the median of
75 mg per day.
During this study, 53 patients (65%) required hospitaliza-
tion for a variety of reasons (Table 3). Some patients had
more than one admission. Based upon the reason for hos-
Table 1: Characteristic of the Study Group at Baseline
No. 81
Male, N (%) 51 (63.0%)
Caucasian, N (%) 60 (74.1%)
Age, mean (range) 51.6 ± 1.5 (22, 88)
ZES, N (%) 63 (76.8%)
MEN – 1, N (%) 6 (7.3%)
Prior antrectomy, N (%) 10 (12.3%)
Serum gastrin concentration, median (range)
ZE 493 (38, 17,491)
Non ZE* 73 (30, 262)
BAO mEq/L, median (range) 22.3 (1.5, 96.5)
MAO mEq/L, median (range) 47.9 (7.2, 121.3)
H. pylori positive, N (%) 52 (64.2%)
* Non ZE – non ZE acid hypersecretorsBMC Gastroenterology 2008, 8:18 http://www.biomedcentral.com/1471-230X/8/18
Page 3 of 4
(page number not for citation purposes)
pitalization, review of hospital records, and discussion
with the patient, antibiotics were provided during the hos-
pitalization in 38 patients (72%). Additional antibiotic
use as an outpatient was reported in 42 patients (52%).
Antibiotic classes used included pencicillin/cepha-
losporin (40%), fluroquinolones (20%), metronidazole
(19%), sulfa macrolide (15%), sulfa (2%), and other
(10%). Some patients took antibiotics of different classes
during the study period. Only one patient reported any
significant gastroenteritis during the study period. This
patient following travel outside the U.S. experienced sev-
eral days of watery diarrhea which was apparently self lim-
ited. He was evaluated by a physician and his stool tests
were negative for any infection. No patient was diagnosed
with C. difficile colitis or bacterial gastroenteritis. Recall
for the specific antibiotics taken, however, was infrequent.
Discussion
Long-term follow-up in a large cohort of acid hypersecre-
tors with known gastric acid secretory status while on lan-
soprazole therapy failed to identify any evidence of
significant gastrointestinal infections. With our extensive
years of treatment and follow-up, only one patient sought
medical care for a reported gastroenteritis and there were
no apparent hospitalizations for gastrointestinal infection
during this study.
The relationship between proton pump inhibitor therapy
and other acid suppressing medications and the risk of
gastrointestinal infections remains controversial. Since
the initial use of histamine-II receptor antagonists in
1973, there has been concern about the possibility of gas-
trointestinal infections with the use of these agents, pre-
sumably related to fecal-oral transmission of bacteria,
which were not killed by an acid milieu in the stomach.
More recent epidemiological studies have focused on
drugs inhibiting gastric acid secretion and the develop-
ment of C. difficile colitis. For example, in a prospective
case controlled study of 155 consecutive inpatients with
C. difficile diarrhea, 92% had received acid suppression
compared with 50% of controls [4]. Logistic regression
also identified acid suppression (odds ratio 1.9, 94% CI
1.1, 3.29) as a risk factor. Large epidemiological studies
also support an association [3]. However, other studies,
primarily retrospective case control studies, have failed to
show an association [9,10]. A population based case con-
trol study from Canada where patients were matched
based on age and gender, as well as antibiotic, found no
association between PPI use and hospitalization for C. dif-
ficile disease [11]. One might anticipate a heightened risk
of infections in patients with pernicious anemia, but this
has been surprisingly not well documented in any large
case series.
In vitro studies show that normal gastric juice with a pH <
4 is bactericidal while achlorhydric gastric juice is not
[12]. At a gastric pH < 3, bacteria instilled in the normal
human stomach are killed, but may remain viable for an
hour in the achlorhydric stomach [13]. In healthy volun-
teers, the use of proton pump inhibitor therapy consist-
ently elevates gastric pH. The 24 hour intragastric pH may
remain > 4 ranging from 40%- over 65% of the monitor-
ing period in patients enrolled in short term studies [14-
17]. Gastric acid analysis in our acid hypersecretor cohort
showed consistently blunted acid secretion yet with sham
feeding stimulation, the basal gastric pH was still < 3.5 in
67%, and with pentagastrin (the equivalent of food) in
84%.
Table 3: Broad indications for hospitalization
N (%)
Surgery 12 (23)
Chest pain/heart disease 11 (21)
Infection 9 (17)
Nausea/vomiting Central nervous system disorder 7 (13) 5 (9)
Other* 13 (25)
* Other – lung disease (4), nephrolithiasis (3), abnormal liver tests (3), 
anemia (1), gout (1), dehydration (1)
Some patients had more than one hospitalization.
Table 2: Duration on PPI, acid outputs, and pH before and during treatment with lansoprazole
N = 81 Before Lansoprazole After Lansoprazole
Duration on PPI (Years) 1.2 ± 0.2 7.1 ± 0.6
Median (range) 0.8 (0.1, 5.0) 6.25 (0,16)
Acid output
BAO (mmol/h) 25.1 ± 1.9 2.4 ± 0.3
PAO (mmol/h) 51.0 ± 2.9 10.4 ± 1.0
pH Median (range)
Basal pH 1.2 (1.0, 8.2) 2.9 (1.1, 8.1)
Stimulated pH 1.1 (1.0, 8.0) 1.6 (1.0, 8.2)BMC Gastroenterology 2008, 8:18 http://www.biomedcentral.com/1471-230X/8/18
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Our study has several limitations which should be recog-
nized. Firstly, while patients were seen on an every six
month basis and were queried regarding hospitalizations,
need for surgery, and intercurrent medication use,
patients were not prospectively queried at each point in
time regarding the development of any gastrointestinal
infections. Secondly, while antibiotic use was assessed,
most patients could not recall nor was there documenta-
tion in many cases of the specific antibiotic and dose used,
but only the class of drug. Thirdly, querying patients
regarding any gastrointestinal infection in some patient's
years after study enrollment could lead to recall bias. Nev-
ertheless, all hospitalizations were documented. Fourth,
depending on the absolute risk of infection with these
infections, our sample size may be inadequate, yet our
long term follow-up assessed by patient years is extensive.
One might have expected more reported episodes of
diarrheal illness but we focused on those more severe
where health care input was sought. Lastly, our study pop-
ulation consists of acid hypersecretors which may be dif-
ferent than those with underlying normal acid secretion
who may have less acid secretion while on PPI therapy.
Conclusion
In conclusion, our large prospective cohort study of
patients with acid hypersecretory states including ZES
undergoing twice yearly evaluations and gastric acid anal-
ysis failed to identify patients experiencing gastrointesti-
nal infections at a median follow-up of greater than six
years. Further long-term follow-up is important to assess
for any infection risk in our cohort.
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